Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study to evaluate CYB 003 in Alcohol Use Disorder

Next Previous
X
Search
Trial Profile

A clinical study to evaluate CYB 003 in Alcohol Use Disorder

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 17 Feb 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CYB 003 (Primary)
  • Indications Alcoholism
  • Focus Adverse reactions; First in man
  • Sponsors Cybin

    • Most Recent Events

    • 10 Feb 2022 According to Cybin media release, Completed Scientific Advice meeting with UK MHRA to support Phase 1/2a trial of CYB003 planned for mid-2022 -
    • 15 Nov 2021 According to Cybin media release, the company expects to submit an investigational new drug application (IND) to the U.S. Food and Drug Administration (the FDA), and a clinical trial application with the U.K. Medicines and Healthcare Products Regulatory Agency in Q2 2022.
    • 19 Oct 2021 According to Cybin media release, the company expect to initiate this study in early 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top